Aditxt’s Subsidiary, Pearsanta, Inc. Engages Spartan Capital as Lead Underwriter for its Planned IPO Intending to Drive Clinical Validation and Commercial Rollout of Its Mitomic™ Platform Technology for Early Detection of Cancers and Other Diseases
Planned IPO Aligns with Aditxt’s Acquire, Build and Capitalize (ABC) Monetization Framework MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today announced…